AccuType® Warfarin
Also known as: CYP2C9, 2C9, Vitamin K Epoxide Reductase Complex, Coumadin, VKORC1
Use
The AccuType® Warfarin test is a germline pharmacogenomic assay that evaluates genetic variants in two genes—CYP2C9 and VKORC1—to predict an individual’s likely response to warfarin therapy, aiding in dose optimization and reducing risk of adverse drug response.
Special Instructions
Informed consent requirements by physician attestation apply in certain states (AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD, VT, and when performed in MA). Ordering can be via whole blood (EDTA preferred) or saliva (Oragene DNA self‑collection kit).
Limitations
Only assesses variants in CYP2C9 and VKORC1; does not account for other genetic, clinical, or environmental factors influencing warfarin metabolism and dosage requirements.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
EDTA (lavender‑top) tube; also acceptable: ACD‑A or ACD‑B (yellow‑top) tube; sodium or lithium heparin tube (green‑top) or sodium heparin (royal blue‑top) tube